Table IV. Estimated site occupancy of IgM N-glycosylation sites N46, N209, N272, N279 and N439.
| Unmodified peptide area | Labeled D18O peptide area | % Occupied | Unmodified peptide area | Labeled D18O peptide area | % Occupied | ||
|---|---|---|---|---|---|---|---|
| IgM-N46 | IgM-N209 | ||||||
| Donor 1A | ND | 2.38E+08 | HIGH | Donor 1A | ND | 5.11E+07 | HIGH |
| Donor 1B | ND | 2.41E+08 | HIGH | Donor 1B | ND | 5.52E+07 | HIGH |
| Donor 1C | ND | 2.49E+08 | HIGH | Donor 1C | ND | 6.10E+07 | HIGH |
| Donor 2A | ND | 3.10E+08 | HIGH | Donor 2A | ND | 4.76E+07 | HIGH |
| Donor 2B | ND | 2.96E+08 | HIGH | Donor 2B | ND | 5.35E+07 | HIGH |
| Donor 2C | ND | 3.05E+08 | HIGH | Donor 2C | ND | 6.36E+07 | HIGH |
| Donor 3A | ND | 1.18E+08 | HIGH | Donor 3A | ND | 1.79E+07 | HIGH |
| Donor 3B | ND | 1.15E+08 | HIGH | Donor 3B | ND | 1.80E+07 | HIGH |
| Donor 3C | ND | 1.14E+08 | HIGH | Donor 3C | ND | 3.30E+07 | HIGH |
| Donor 4A | ND | 1.10E+08 | HIGH | Donor 4A | ND | ND | - |
| Donor 4B | ND | 9.49E+07 | HIGH | Donor 4B | ND | ND | - |
| Donor 4C | ND | 9.91E+07 | HIGH | Donor 4C | ND | 1.16E+05 | HIGH |
| IgM-N272 | IgM-N279 | ||||||
| Donor 1A | ND | 9.43E+06 | HIGH | Donor 1A | ND | 3.42E+09 | HIGH |
| Donor 1B | ND | 8.63E+06 | HIGH | Donor 1B | ND | 3.26E+09 | HIGH |
| Donor 1C | ND | 7.26E+06 | HIGH | Donor 1C | ND | 3.22E+09 | HIGH |
| Donor 2A | ND | 6.78E+06 | HIGH | Donor 2A | ND | 4.42E+09 | HIGH |
| Donor 2B | ND | 7.08E+06 | HIGH | Donor 2B | ND | 4.49E+09 | HIGH |
| Donor 2C | ND | 7.75E+06 | HIGH | Donor 2C | ND | 4.62E+09 | HIGH |
| Donor 3A | ND | 8.21E+06 | HIGH | Donor 3A | ND | 1.85E+09 | HIGH |
| Donor 3B | ND | 8.20E+06 | HIGH | Donor 3B | ND | 1.75E+09 | HIGH |
| Donor 3C | ND | 8.09E+06 | HIGH | Donor 3C | ND | 1.65E+09 | HIGH |
| Donor 4A | ND | 2.83E+06 | HIGH | Donor 4A | ND | 1.64E+09 | HIGH |
| Donor 4B | ND | 1.86E+06 | HIGH | Donor 4B | ND | 1.51E+09 | HIGH |
| Donor 4C | ND | 1.37E+06 | HIGH | Donor 4C | ND | 1.32E+09 | HIGH |
| IgM-N439 | |||||||
| Donor 1A | 1.85E+07 | 9.29E+06 | 33.39% | ||||
| Donor 1B | 1.65E+07 | 8.16E+06 | 33.09% | ||||
| Donor 1C | 1.70E+07 | 7.73E+06 | 31.21% | ||||
| Donor 2A | 2.81E+07 | 1.43E+07 | 33.70% | ||||
| Donor 2B | 2.68E+07 | 1.52E+07 | 36.13% | ||||
| Donor 2C | 2.82E+07 | 1.47E+07 | 34.31% | ||||
| Donor 3A | 3.36E+06 | 1.73E+06 | 34.06% | ||||
| Donor 3B | 2.95E+06 | 1.55E+06 | 34.46% | ||||
| Donor 3C | 3.40E+06 | 1.77E+06 | 34.26% | ||||
| Donor 4A | 7.37E+06 | 6.01E+06 | 44.91% | ||||
| Donor 4B | 7.50E+06 | 4.76E+06 | 38.84% | ||||
| Donor 4C | 6.34E+06 | 4.54E+06 | 41.73% |
Results of triplicate analyses are shown.